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Study design: A two center, observational study.
Introduction: Patient reported outcome (PRO) plays an increasingly important role in
the evaluation of novel therapies for tumor patients. It has been shown that tumor treating
fields (TTFields) in combination with standard therapy prolong survival in high-grade
glioma (hgG) patients. But critics claim that TTFields significantly impacts patients’
everyday life due to side effects and average daily time on therapy (18 h) in a patient
population with very limited life expectancy and high symptom burden. However, very
limited data exist on PRO for TTFields treatment.
Methods: This two center, observational study describes PRO of 30 hgG patients
receiving TTFields in combination with chemotherapy. We introduced a device-specific
questionnaire (DSQ) addressing device-specific restrictions and impact on daily live after
2 months of therapy. Additionally following questionnaires were used: EORTC (European
Organization for Research and Treatment of Cancer), QLQ-30 (Quality of life of cancer
patients), QLQ BN20 (Quality of life brain cancer module), QLQ FA13 (Cancer-related
fatigue), and SSUK-8 (social support).
Results: Surveys have been completed by 91% of enrolled patients. EORTC QLQ-30
revealed better physical, emotional, and cognitive function than social and role function
of study cohort. TTFields users reported frequently on positive social support and a low
level of detrimental interactions. Seventy one percent of patients felt affected in daily
life due to TTFields at least 2–3 times per week up to several times per day while
maintaining high therapy compliance. Most frequent device-specific restrictions were
duration of therapy (74%), size (66%), and weight (70%) of the device and changing
time and bonding of the transducer arrays (66%, mean duration: 43.6min). Restrictions
on exercise of hobbies/work (63%/61%), body care (71%), and sexuality/relationship
(64%) were most relevant. Seventy percent would recommend TTFields to others
and 67% would reuse TTFields treatment again based on their current experience.
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Conclusion: The study shows that although TTFields treatment frequently affects
everyday life in all aspects, therapy compliance was high and 67% of patients would
reconsider TTFields for themselves. We propose that findings of PRO be taken into
account for medical consultation about TTFields and in future device development to
deliver high-value patient-centered care.
Keywords: patient reported outcome (PRO), glioblastoma, TTFields treatment, quality of life (QoL), therapy
compliance
INTRODUCTION
Standard treatment of a newly diagnosed high-grade glioma
(hgG) involves surgical resection of the tumor followed by
concomitant radiochemotherapy andmaintenance therapy using
the alkylating cytostatic temozolomide (TMZ) (1). With Tumor
treating fields (TTFields), an additional treatment modality has
been introduced. Its efficacy has been proven in a randomized
controlled trial (2, 3). TTFields are alternating electric fields
generated by a mobile device system, and applied at low intensity
(0.7 V/cm) and medium frequency (200 kHz) via transducer
arrays positioned on the shaved scalp in the area of the
tumor (TTFields R© Instructions For Use, 2016) (4, 5). Highest
effectiveness is achieved when using TTFields more than 75%
of the time, translating into daily time on therapy of 18 h
or more (6, 7). In a recent analysis among participants in
the EF-14 study, validated questionnaires from the European
Organization for Research and Treatment of Cancer (EORTC)
did not show any relevant difference of health related QoL
(HrQoL) in patients receiving TMZ plus TTFields or TMZ
alone except skin irritations (8). In fact, only 65.8% completed
HrQoL assessment at 3 months and only 41.7% of the surviving
study participants have been evaluated for HrQoL at 12-months
follow up (8). In addition, device-specific restrictions on daily
life may not have been translated into the more “general”
EORTC questionnaire.
Here, we aim to assess patient-reported outcome (PRO)
including motivation for therapy, nature, and frequency of
TTFields-specific complaints and their impact on daily life
introducing a device-specific questionnaire (DSQ).
MATERIALS AND METHODS
Study Design
Patients were informed about TTFields treatment using the
formerly introduced staged approach (9). Between June 2015 and
June 2017, patients with hgG including anaplastic astrocytoma
and glioblastoma, who have already completed 2 months
of TTFields treatment, were included in the PRO-study at
two institutions. Thirty out of 33 patients returned the
completed questionnaire. None of the patients experienced
tumor recurrence/progression during the observation period.
Patients received TTFields treatment in addition to first or
second line chemotherapy. PRO was routinely assessed with
EORTC questionnaires QLQ-30 (Quality of life of cancer
patients), QLQ BN20 (Quality of life brain cancer module),
QLQ FA13 (Cancer-related fatigue), SSUK-8 (social support),
andDSQ 2months after therapy initiation. Twenty seven patients
deemed suitable for TTFields treatment but refused TTFields
treatment served as control group. They completed EORTC
QLQ-30, QLQ BN20, QLQ FA13, and SSUK-8 2 months after
initiation of cyclic TMZ. Local ethic’s committee agreed to the
study (Vote#EA4/028/17).
Introduction of a Device-Specific
Questionnaire (DSQ)
Since standard EORTC based QoL assessment might not
fully reflect TTFields-specific restrictions on daily life, a DSQ
has been developed in cooperation with the department of
psychooncology, Charité Comprehensive Cancer Center, Berlin,
Germany. DSQ has been completed at 2 months of TTFields
treatment allowing evaluation of therapy after an adjusting
phase. Patients were asked about information resources regarding
TTFields treatment and about motivation for therapy. They
were queried to retrospectively score subjective changes in QoL
before, 1 and 2 months after TTFields treatment at a visual
analog scale ranging from 0 to 10 (0 points = poor QoL,
10 points = excellent QoL). We inquired about disturbing
factors like nightly operating time, visibility of transducer
array, total duration of therapy, financial and administrative
procedures, device alarming, side effects (e.g., skin irritation),
change and bonding of transducer arrays, battery capacity, size
and weight of the device, and head shaving. We specifically
requested information regarding when and how often device
alarming occurred, what kind of side effects occurred and
how often side effects led to therapy interruption. Further,
we asked for the time needed for change and bonding
of transducer arrays and adaption to therapy. Concerning
TTFields impact on everyday life, the following items were
assessed: mobility at home and outside, exercises of work,
hobbies, housework, shopping, sleep, sexuality/relationship, and
motivation for therapy. Individual items could be evaluated with
the following answers: very severe restriction (several times per
day), severe restriction (several times per week/once a day),
moderate restriction (2–3 times per week), mild restrictions
(<2–3 times per week), no restrictions or improvement due to
TTFields. Furthermore, patients should express their degree of
recommendation of TTFields to others and whether they would
reconsider TTFields as therapeutic option for themselves at their
current knowledge. The English version of the DSQ is attached
as Supplementary Material.
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Survey Instruments
The EORTC QLQ-C30 (Version 3.0) provides a comprehensive
overview of subscales and multiple items to assess functional
integrity, symptom burden, and overall health in oncological
patients, based on a total of 30 unique questions on various
factors of HrQoL (10, 11). For each subscale and each item,
a score is obtained (0–100) which is proportional to the
degree of physical and psychological function, to the direct
holistic assessment of health status, and to the manifestation
of symptoms (10). For assessment of patients’ disease-specific
quality of life, an add-on module EORTC QLQ-BN20 was used.
In order to depict the particular relevance of physical, emotional
and cognitive fatigue, EORTC QLQ-FA13 was added (12, 13).
The determination of the score and the interpretation of the
results for both questionnaires was conducted as described in
the literature (10, 14–16). The shortened version of the Illness-
specific Social Support Scale SSUK consists of a total of 8 items,
of which 4 in the form of a sum score capture the importance
of both negative and positive interactions between patients and
their caregivers (17, 18).
Statistical Analysis
Statistical analysis was performed using Microsoft Excel
(Microsoft Cooperation, Redmond, WA, USA) and GraphPad
Prism 5 (GraphPad Software, La Jolla, CA, USA). The
details of the DSQ were predominantly descriptively evaluated.
Independent measures of two groups were performed with
the Student’s T-test, independent measures of more than two
groups with one-way ANOVA Bonferroni multicomparison test.
For non-parametric data, summary data was given as means,
median and range. 95% confidence interval (95% CI) were given,
significance level was set at p< 0.05. Analysis of quality of life was
carried out according to the EORTCmanual. For global quality of
life scale and the functional scales; higher scores correspond with
higher functioning and so better quality of life (19). Whereas, for
symptom scales and single items; higher scores correspond with
more symptoms, high distress and impairment, and indicate a
worse quality of life. A difference of more than 10 points was
considered clinically meaningful (15).
RESULTS
Study Cohort
Thirty patients with diagnosis of a hgG were included in the
study (Glioblastoma n = 28, anaplastic astrocytoma n = 2).
Mean age was 50 years (median: 52 years, range: 36–64), male
predominance was present with 67%. IDHwasmutated in 13% of
cases, MGMT promoter methylation was apparent in 43%. Gross
total tumor resection was achieved in 80%. Fourteen patients
started TTFields in combination to first line chemotherapy
(cyclic TMZ). Therapy compliance was on average 83% (range
40–97%) during the first month and 85% (range 56–97%) during
the second month of TTFields treatment. The control group
consisted of 27 patients with glioblastoma receiving standard
treatment with concomitant radiochemotherapy and cyclic TMZ.
Detailed patients characteristics of intervention group and
control group are given in Table 1.





Age (mean) 50 years 47 years
Gender n (%)
Female 10 (33%) 8 (30%)
Male 20 (67%) 19 (70%)
Histology
Glioblastoma 28 (93%) 27 (100%)
Anaplastic astrocytoma 2 (7%) –
Stage of disease
1st line 14 (47%) 27 (100%)
2nd line 16 (53%) –
Combined therapy
cTMZ 14 (47%) 27 (100%)
mTMZ 6 (20%) –
CCNU 4 (13%) –
BEV 1 (3%) –
PC 1 (3%) –
NA 4 (13%) –
IDH status
Wildtype 21 (70%) 2 (7%)
Mutant 4 (13%) 1 (4%)
NA 5 (17%) 24 (89%)
MGMT status
Methylated 13 (43%) 1 (4%)
Unmethylated 12 (40%) 2 (7%)
NA 5 (17%) 24 (89%)
Extend of resection
Gross total resection 24 (80%) –
Biopsy/partial resect. 5 (17%) –
NA 1 (3%) 27 (100%)
BEV, Bevacizumab; CCNU, Lomustine; cTMZ, cyclic Temozolomide; IDH, Isocitrate
dehydrogenase; MGMT, O6-methylguanin-DNA-methyltransferase; mTMZ, metronomic
Temozolomide; NA, Not Assessed; PC, Procarbazine and Lomustine.
Mean score of HrQoL assessed with EORTQLQ-C30 was 50.3
in the intervention group and 45.7 in the control group (p =
not significant). The lack of future prospects for glioblastoma
patients was one of the central brain tumor-specific factors,
which had a highly negative impact on HrQoL in both
study groups. Patients who received additional treatment with
TTFields showed better emotional function compared to the
control group (∗∗p < 0.01). At the same time, patients had a
significantly lower incidence of insomnia and loss of appetite
(p < 0.01) and, to a lesser extent, pain, dyspnea, nausea, and
vomiting (p < 0.05). Results of the EORTC QLQ BN-20 showed
no significant differences between groups in means of severity of
neurological symptoms due to brain tumor disease. Patients of
the intervention group showed clinically relevant better physical,
emotional, and cognitive function compared to role function and
social function (EORTC QLQ-C30, Figure 1A). The following
symptom scale items affected HrQoL the most: fatigue followed
by insomnia, constipation, and financial difficulties (EORTC
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FIGURE 1 | Results of EORTC QLQ-C30, EORTC QLQ-BN20, and EORTC QLQ-FA13 assessed at 2 month of TTFields treatment. Mean scores (X-axis) range from 0
to 100%, which are proportional to the degree of function or symptom load. In the function scales higher scores represent a better level of functioning while in the
case of symptom scales/items higher scores mark a higher level of symptomatology or problems. (A) Health related quality of life (HRQoL) and functional scales items
from EORTC QLQ-C30 2 months after TTFields start. (B) EORTC QLQ-C30 symptom scale 2 months after TTFields start. (C) EORTC QLQ-BN20 2 months after
TTFields start. (D) Presence of fatigue assessed with EORTC QLQ-FA13 2 months after TTFields start. (E) Social support and detrimental interaction assessed with
SSUK-8 2 months after TTFields start. EORTC, European Organization for Research and Treatment of Cancer; QLQ-BN20, Quality of life brain cancer module;
QLQ-C30, Quality of life of cancer patients; QLQ-FA13, cancer-related fatigue.
QLQ-C30, Figure 1B). Brain tumor specific concerns/symptoms
were in descending frequency: future uncertainty, drowsiness,
motor dysfunction/weakness of legs, and communication deficits
(EORTC QLQ-BN20, Figure 1C). Cognitive fatigue affected less
severely HrQoL than emotional and physical fatigue (EORTC
QLQ-FA13, Figure 1D). TTFields users reported frequently on
positive social support and a low level of detrimental interactions
(SSUK-8, Figure 1E). Although, no significant difference was
detected in terms of stressful interactions with the social
environment, intervention group received more positive social
support in their daily lives relative to the control group.
Motivation for TTFields and PRO
Eighty one percent of patients were initially
informed about TTFields treatment by their treating
oncologist/neurosurgeon/radiooncologist. Eleven percentage
received information about TTFields via internet or patient
platforms. The decision for TTFields treatment was mostly
motivated by the feeling of actively doing something against
the tumor (100%), the proposed additive therapeutic effect of
TTFields to standard therapy (73.3%), the new therapeutic
concept (76.6%), and recommendation of the treating
physician (96%).
Patients needed an average of 24 days (median: 14 days,
range: 0–90 days) to adapt to the therapy. Patients retrospectively
rated their QoL since the start of TTFields treatment. They
reported on a decrease of QoL 1 month after TTFields
initiation, which normalized in 90% of cases to initial status
after 2 months of TTFields treatment. Most frequent side
effects written in the answer portion of the DSQ were skin
TABLE 2 | Usability and side effects of TTFields.
MV Range
Frequency of device alarming
Day time 3.5 1–10
Night time 2.0 1–20
Time needed for bonding of arrays (min) 47 15–150
Side effects
Skin irritations 40% –
“Electro shocks” 3% –
Posture-related complications 3% –
Psychological complaints 10% –
irritations (40%), such as pruritus, erythema, and secondary
eﬄorescence among the transducer arrays as well as posture-
related complications (e.g., back pain due to carrying the
device in a single shoulder strap bag, 3%). In addition, 10%
felt a causal relationship of psychological complaints such as
depression and nervousness under TTFields. As a result of
these adverse effects, 6 patients performed an average of 2.7
therapy breaks. Detailed information on usability and side effects
are given in Table 2. The following device-specific restrictions
had a moderate to very severe impact on everyday life in the
majority of our patients: size (62%) and weight (67%) of the
device, changing time and bonding of the transducer arrays (57%,
mean duration: 47min, median: 30min, range 15–150min) and
daily duration of therapy (54%). Device alarming was rated
moderate to very severely disturbing in 70%. Alarms occurred
on average 3.5 times during the day and 2.0 times during
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FIGURE 2 | PROMs using a device-specific questionnaire completed 2 months after TTFields initiation addressing device-specific complains. PROMs,
patient-reported outcome measures.
the night. The following topics were rated to not or mildly
restricting everyday life in the majority of patients: head shaving
(55%), visibility of transducer arrays (64%), side effects like skin
irritations (65%), nightly operating time (67%), and therapy
costs (76%) (Figure 2).
Seventy one percent of all patients faced moderate to very
severe restrictions on everyday life due to TTFields treatment.
TTFields caused moderate to very severe restriction in exercise
of hobbies (63%) and work (61%), and mobility outside home
(57%). Own body care was significantly affected in 71%. Seventy
four percent reported on moderate to very severe restrictions in
sexuality and relationship. Mild or no restrictions were reported
on mental stability (61%), interaction with friends/family (67%)
and coworkers (72%). Eleven percentage reported increased
motivation for therapy due to TTFields treatment. Detailed data
is given in Figure 3. Despite the mentioned restrictions, 70%
would recommend TTFields to others, 67%would reuse TTFields
treatment again based on their own experience. 16.5% would not
repeat TTFields treatment, 14.8% did not share their opinion on
the topic.
DISCUSSION
The principal novel findings of the study are that PRO revealed
moderate to very severe restrictions on daily living due to
TTFields in 71% and a transient subjective decline in QoL during
the firstmonth of therapy.Major restrictions existed in exercise of
hobbies/work, own body care and sexuality/relationship. Device
specific complaints were mostly related to device alarming,
change and bonding procedure of arrays, and size and weight
of device. However, these restrictions seem to be balanced
by positive social support, a positive motivation for actively
taking part in therapy and do not translate into poor symptom
scales or worsened QoL compared to a time point before
starting TTFields.
Patients reported an average time of 24 days to adapt to the
therapy, which is reflected in the temporary decline of QoL
1 month after TTFields initiation. After the adaption phase,
only 10% reported on a persistent impairment in QoL due to
TTFields treatment. Overall, QoL of the study cohort assessed
with standardized EORTC questionnaires showed comparable
results to other studies (8, 20, 21). In contrast to Taphoorn
et al., reduced role and social function had the strongest impact
on QoL in our study cohort, which might be a result of the
above mentioned restrictions due to TTFields on daily life
(8). Medically treatable symptoms such as nausea/vomiting,
insomnia, appetite loss, pain, seizures, and headache were
relatively well-controlled in our cohort compared to the general
population normative data and our control group (22), which
could be explained by increased medical and social attention
due to TTFields treatment and selection bias. Device support
specialists who support the patients at home may have picked up
symptoms earlier than at the next physician appointment leading
to earlier symptom detection and therapy. Good emotional
functioning and high social support within the study cohort
might also have contributed to good symptom control and, in
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FIGURE 3 | Impact of TTFields on everyday life assessed with a device-specific questionnaire completed 2 months after therapy initiation.
turn, confirm proper patient selection (9). Although TTFields
treatment frequently affects daily life in all aspects, 67% would
reconsider TTFields for themselves and 11% reported improved
motivation due to TTFields therapy. However, 1 out of 6
patients would not consent to treatment again leaving room
for improvement on the device regarding overall practicability
(arrays, batteries, carrying the device). Our study also has some
limitations, which restrict the interpretation of our data: (i)
usage of a non-validated questionnaire; (ii) missing baseline
and long term follow up on QoL; and (iii) non-randomized
study with potential selection bias. For this reason, prospective
randomized controlled trials that provide the same level of
medical and social attention to the control group are important to
objectify QoL and therapy response. However, understanding the
patient perspective on newly introduced, oncological therapies
like TTFields is integral to delivering high-value patient-
centered care.
In summary, we propose that PRO of our study be taken
into account for medical consultation about TTFields and in
the future development of the device. Results of PRO might
help to better inform patients about suspected restriction
and in turn increase acceptance and compliance toward
TTFields treatment.
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